Power Wheelchair Group 2 denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's Commercial policy states that mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POVs), canes, and walkers are a covered health care service when medically necessary. The policy applies the Medicare DME MAC LCD for Power Mobility Devices (L33789) criteria, which require that the beneficiary has a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home, where the mobility limitation prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completion within a reasonable time frame. The beneficiary's mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. For a Group 2 Single Power Option PWC (K0835–K0840), all basic coverage criteria (a)–(e) must be met, plus the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick (e.g., head control, sip and puff, switch control), OR meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair, AND has had a specialty evaluation performed by a licensed/certified medical professional (PT, OT, or practitioner) with specific training and experience in rehabilitation wheelchair evaluations documenting medical necessity. The wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. Section 6407 of the ACA requires a face-to-face encounter, documented by a physician (or NP, PA, or CNS), occurring within the 6 months before the order is written for the DME. Weight-class criteria apply: a Heavy Duty PWC is covered for beneficiaries weighing 285–450 pounds, Very Heavy Duty for 428–600 pounds, and Extra Heavy Duty for 570 pounds or more. Payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document in-home MRADL impairment in detail** — Provide specific examples of how the member cannot independently/safely complete toileting, feeding, dressing, grooming, or bathing in the home, mapping directly to the LCD MRADL definition: a mobility limitation that prevents accomplishment of an MRADL, places the beneficiary at heightened risk of morbidity/mortality, or prevents completion within a reasonable time frame. - **Demonstrate failure of lesser alternatives** — Include PT/OT trial documentation showing that the beneficiary lacks sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day due to weakness, fatigue, pain, ROM limits, or absent extremities, satisfying LCD basic criterion C. - **Submit a compliant specialty evaluation and ATP attestation** — Provide the LCMP/PT/OT evaluation with the no-financial-relationship attestation per the requirement of a signed and dated attestation by the supplier or LCMP that the LCMP has no financial relationship with the supplier , plus documentation that the wheelchair is provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. - **Justify the Group 2 power option upgrade** — For K0835–K0840, document either a non-standard drive control need (head control, sip-and-puff, switch) OR concurrent need for a power tilt/recline system per the LCD requirement that the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick, or meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair. - **Provide a timely 7-element order and face-to-face note** — Submit the in-window F2F note and order; per the LCD policy article, the 7-element order must be received by the supplier within 45 days after completion of the face-to-face examination , and per CMS, the encounter must occur within the 6 months before the order is written. - **Verify accurate weight-class coding** — Confirm the member's weight aligns with the prescribed class boundaries set by the LCD: Heavy Duty 285–450 lb, Very Heavy Duty 428–600 lb, and Extra Heavy Duty 570 lb or more , and amend the HCPCS code if a misclassification triggered the denial. - **Cite clinical/professional standards** — Reference RESNA's position papers on the application of power wheelchairs and seat-elevation/tilt systems, and AOTA/APTA wheelchair assessment guidelines, to support the medical necessity narrative that mirrors LCD L33789 — the framework UnitedHealthcare explicitly adopts via its Mobility Devices policy and the DME MAC LCD for Power Mobility Devices (L33789).

## Why UnitedHealthcare Denied Your Group 2 Power Wheelchair as "Non-Formulary"

The term "non-formulary" technically applies to drugs, but UHC and other insurers sometimes use it — or analogous language — for durable medical equipment when a specific device model, brand, or configuration is not on UHC's preferred or contracted DME product list. This effectively means UHC will not cover that particular model at the standard benefit level, or at all, without an exception. The device may be clinically equivalent to approved models but simply not listed with the contracted supplier network.

## Why This Denial Is Appealable

Non-formulary (or non-preferred) DME denials are regularly overturned when the patient can demonstrate that the requested device is medically necessary and that a formulary alternative either does not exist, is not clinically appropriate, or is not available through a contracted supplier. Federal law and plan terms typically provide a process for requesting a coverage exception on clinical grounds.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plans) or applicable state insurance law. The deadline appears on your EOB.
• External review: ACA §2719 provides access to independent external review after a final adverse internal decision. An independent reviewer will assess whether the non-formulary classification is appropriate given your clinical needs.
• Expedited review: Available when waiting poses a risk to your health or functional independence.
• Window: External review must generally be requested within four months of a final internal adverse determination.

## Concrete Appeal Steps

1. Ask UHC for a list of formulary (preferred) Group 2 power wheelchair models and suppliers. 2. Have your prescribing physician or certified rehabilitation technology supplier evaluate whether any preferred alternative meets your clinical needs. 3. If no preferred alternative is appropriate, have the prescriber document in writing why the non-formulary device is medically necessary. 4. Submit a written formulary-exception request or internal appeal with clinical documentation attached. 5. Escalate to external review if denied internally.

## Documentation to Gather

• UHC's list of covered/preferred Group 2 wheelchair models and suppliers
• Clinical assessment explaining why the requested device — and not a formulary alternative — is required
• Prescriber letter of medical necessity referencing UHC's formulary-exception criteria
• Functional mobility assessment from a physical or occupational therapist or physiatrist
• Diagnosis records and history of mobility-limiting condition

## Criteria-Mapping Structure

Obtain UHC's DME formulary-exception policy. For each criterion required to grant an exception, provide the corresponding clinical fact from the chart. Key criteria typically include medical necessity of the specific model, inadequacy of formulary alternatives, and treating-clinician attestation. Address each criterion directly and explicitly in your appeal letter.